Steven Cohen Corvus Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $36 Billion
- Q2 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 5,964,510 shares of CRVS stock, worth $52.4 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
5,964,510
Previous 5,964,510
-0.0%
Holding current value
$52.4 Million
Previous $10.9 Million
-0.0%
% of portfolio
0.03%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding CRVS
# of Institutions
55Shares Held
27.8MCall Options Held
22.9KPut Options Held
29.8K-
Orbimed Advisors LLC San Diego, CA6.94MShares$61 Million0.3% of portfolio
-
Samlyn Capital, LLC New York, NY6.12MShares$53.8 Million0.2% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$28.8 Million2.69% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.65MShares$14.5 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny564KShares$4.96 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $409M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...